Evolution of Medicare Formulary Coverage Changes for Antithrombotic Therapies After Guideline Updates-Reference-Cited by-同舟云学术

Evolution of Medicare Formulary Coverage Changes for Antithrombotic Therapies After Guideline Updates

Published:2019-10 Issue:14 Volume:140 Page:1227-1230
ISSN:0009-7322
Container-title:Circulation
language:en
Short-container-title:Circulation

Author:

Dayoub Elias J.¹²,Ross Joseph S.³⁴⁵,Shah Nilay D.⁶,Dhruva Sanket S.⁷⁸

Affiliation:

1. Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA (E.J.D.).

2. Center for Cardiovascular Outcomes, Quality, and Evaluative Research, and the Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia (E.J.D.).

3. Center for Outcomes Research and Evaluation, Yale-New Haven Health System, CT (J.S.R.).

4. Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT (J.S.R.).

5. Department of Health Policy and Management, Yale School of Public Health, New Haven, CT (J.S.R.).

6. Division of Health Care Policy and Research and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN (N.D.S.).

7. San Francisco Veterans Affairs Medical Center, CA (S.S.D.).

8. Division of Cardiology, Department of Medicine, University of California, San Francisco School of Medicine (S.S.D.).

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference5 articles.

1. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons

2. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary

3. Antithrombotic Therapy for VTE Disease

4. Cubanski J Damico A Neuman T. Kaiser Family Foundation. Medicare Part D: A First Look at Prescription Drug Plans in 2019. http://files.kff.org/attachment/Issue-Brief-Medicare-Part-D-A-First-Look-at-Prescription-Drug-Plans-in-2019. Published October 16 2018. Accessed June 5 2019.

5. Centers for Medicare & Medicaid Services. Medicare Part D Drug Spending Dashboard & Data. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Information-on-Prescription-Drugs/MedicarePartD.html. Accessed February 28 2019.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Payer approval and rejection of oral anticoagulant prescriptions and prescription abandonment patterns among patients with venous thromboembolism;Journal of Managed Care & Specialty Pharmacy;2024-01-26

2. Overcoming Challenges to Implementing New Evidence for Low-Dose Anticoagulant Use in Peripheral Artery Disease;Circulation;2023-12-12

3. Comparing U.S. and Canadian treatment patterns on venous thromboembolism outcomes in the GARFIELD-VTE registry;Thrombosis Research;2023-12

4. The association between warfarin usage and international normalized ratio increase: systematic analysis of FDA Adverse Event Reporting System (FAERS);The Journal of Cardiovascular Aging;2023-10-17

5. Disparities in adoption of new diabetic therapies with cardiovascular benefits;Diabetes Research and Clinical Practice;2023-02